Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)

Míreanna comhchosúla

• EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS
  de réir: Emery, P, et al.
  Foilsithe / Cruthaithe: (2012)
• Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
  de réir: Baeten, D, et al.
  Foilsithe / Cruthaithe: (2013)
• EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
  de réir: Van Laar, J, et al.
  Foilsithe / Cruthaithe: (2012)
• Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging
  de réir: Baraliakos, X, et al.
  Foilsithe / Cruthaithe: (2011)
• Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis
  de réir: Baraliakos, X, et al.
  Foilsithe / Cruthaithe: (2013)